预约演示
更新于：2025-04-05
Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.)
更新于：2025-04-05
概要
基本信息
在研机构- |
最高研发阶段无进展临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
77
项与 Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.) 相关的临床试验KCT0009992
A prospective, multicenter study of an etoposide plus G-CSF followed by peripheral blood CD34+ cell count-adapted plerixafor mobilization in transplant-eligible patients with multiple myeloma who have received daratumumab and/or lenalidomide containing-induction therapy: Catholic Research Network for Multiple Myeloma Study
开始日期2025-01-01 |
申办/合作机构- |
ChiCTR2400086291
A prospective, multi-center clinical study of mitoxantrone hydrochloride liposome injection combined with cladribine, cytarabine and granulocyte colony-stimulating factor in the treatment of relapsed and refractory acute myeloid leukemia
开始日期2024-07-01 |
申办/合作机构- |
JPRN-jRCTb030240024
G-CSF-mobilized peripheral blood-derived autologous CD34+ cell transplantation for patients with chronic kidney disease
开始日期2024-06-05 |
申办/合作机构- |
100 项与 Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.) 相关的临床结果
登录后查看更多信息
100 项与 Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.) 相关的转化医学
登录后查看更多信息
100 项与 Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.) 相关的专利（医药）
登录后查看更多信息
13,720
项与 Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.) 相关的文献（医药）2025-12-01·Journal of Gastrointestinal Cancer
FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting
Article
作者: My, Doan Tien ; Anh, Le Tuan ; Trung, Lam Viet ; Bac, Nguyen Hoang ; Tri, Phan Minh ; Hao, Vuong Dinh Thy ; Vuong, Nguyen Lam
PURPOSE:
FOLFOXIRI is a standard treatment for unresectable colorectal cancer (CRC) liver metastases. However, limited data exists on its safety and effectiveness in low-to-middle-income countries (LMICs). This prospective study addresses this gap in a Vietnamese LMIC setting.
METHODS:
We enrolled 92 patients with unresectable CRC liver metastases between 2022 and 2023. All patients received FOLFOXIRI every 2 weeks, with routine G-CSF prophylaxis to prevent neutropenia. A multidisciplinary team (MDT) assessed diagnoses and treatment responses. Outcomes were R0/R1 resection rate, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), adverse events (AEs), and recurrence-free survival (RFS) for surgical patients.
RESULTS:
The median patient age was 56 years, with a male predominance (70.7%). The primary tumors were located in the left colon (42.4%), rectum (37%), and right colon (20.7%). Thirty-two patients (34.8%) experienced severe (grade 3 or higher) AEs, with thrombocytopenia (13.1%) and anemia (9.8%) being the most frequent. Most patients (72/87, 82.9%) achieved a partial response. The ORR and DCR were 85.1% and 95.4%, respectively. Fifty-seven patients (62%) achieved resectability, and 54 (58.7%) underwent radical surgery. The R0/R1 resection rate was 88.9%. The median PFS and OS for all patients were 13 and 22 months, respectively. The median RFS of surgical patients was 14 months.
CONCLUSIONS:
FOLFOXIRI improves the response rates, R0/R1 resection rates, and survivals for patients with CRC liver metastases. Future research is necessary to improve the prognosis of patients while minimizing toxicities.
TRIAL REGISTRATION:
NCT05362825 dated 5 May 2022.
2025-12-01·IMMUNOLOGIC RESEARCH
Immunoenhancing of the anti-cancer therapy and anti-oxidative stress by co-administration of granulocyte-colony stimulating factor-mobilized stem cells or cells derived from bone marrow and/or spleen plus vaccination with chemotherapeutic cyclophosphamide
Article
作者: Gomaa, Soha ; Tabl, Ghada ; Gabry, Shaimaa El ; Nassef, Mohamed
The combination of immunotherapy and chemotherapy, referred to as chemo-immunotherapy, represents a promising regimen for developing new cancer treatments that target the local tumor microenvironment and target tumors in their early stages. However, this approach carries potential risks, including myelo- and immunosuppression, as well as the emergence of chemo-resistant tumor cells. The purpose of this study was to investigate how well mobilizing hematopoietic stem cells (HSCs) work when used alongside chemotherapy and immunotherapy to enhance and modulate the immune response, thereby overcoming immunosuppression and eliminating distant cancer cells. Ehrlich ascetic carcinoma (EAC) tumor-bearing mice were intraperitoneal (i.p.) preconditioned with CTX (4 mg/mouse). EAC-bearing mice that were preconditioned with CTX were intravenous (i.v.) administered with adoptive transferred naive mice-derived bone marrow cells (nBMCs) at 5 × 106 through lateral tail vein (nBMCs group), adoptive transferred tumor-bearing mice-derived bone marrow cells (tBMCs) at 5 × 106 cell/mouse (tBMCs group), a combination of adoptive transferred naïve mice-derived bone marrow cells (nBMCs) and naïve mice-derived splenocytes (nSPs) at 5 × 106 (nBMCs/nSPs group), a combination of adoptive transferred tumor-bearing mice-derived bone marrow cells (tBMCs) and tumor-bearing mice derived-splenocytes (tSPs) at 5 × 106 cell/mouse (tBMCs/tSPs group), or G-CSF administrated subcutaneously (s.c.) at 5 µg/mouse (G-CSF group). Subsequently, all mice groups were vaccinated with tumor lysate at a dosage of 100 µg/mouse. Treating EAC tumor-bearing mice with G-CSF, adoptive transferred nBMCs, adoptive transferred tBMCs, adoptive transferred nBMCs/nSPs, adoptive transferred tBMCs/tSPs, resulted in a significantly enhanced anti-tumor effect that was evidenced by increased anti-proliferative activity and growth inhibition against EAC tumor cells, increased necrosis and apoptosis rates among EAC tumor cells, restricted tumor growth in EAC tumor-bearing mice, and reduced levels of carcinoembryonic antigen (CEA) tumor marker. Furthermore, there was an improvement in serum levels of antioxidant enzyme superoxide dismutase (SOD) and malondialdehyde (MDA) in EAC tumor-bearing mice receiving G-CSF, adoptive transferred tBMCs, adoptive transferred nBMCs/nSPs, and adoptive transferred tBMCs/tSPs. Notably, this treatment regimen ameliorates liver and kidney damage associated with CTX administration in EA tumor-bearing mice. The integration of G-CSF-mobilized HSCs, adoptive transferred nBMCs, adoptive transferred tBMCs, adoptive transferred nBMCs/nSPs combination, and adoptive transferred tBMCs/tSPs combination may yield powerful anti-cancer therapy, thereby facilitating more effective anti-tumor immunotherapy strategies when align with anti-tumor responses. This research may propose a novel therapeutic approach that combines chemotherapy and immunotherapy for addressing early-stage cancer. Further research is necessary to connect the biomedical application and heterogeneity of human tumors and immune systems of this regimen to both diagnostic and therapeutic methodologies.
2025-06-01·TISSUE & CELL
Neuroprotective effects of granulocyte colony-stimulating factor against tramadol-induced cerebellar neurotoxicity
Article
作者: El-Nabalaway, Mohammad ; Albadawi, Emad A ; Ali, Lashin S ; Badawy, Abdelnaser A ; Mostafa, Sally Abdallah ; Elhassan, Yasir Hassan ; Attia, Ghalia Mahfouz ; Elmansy, Rasha Ahmed ; Elsaed, Wael M ; Eldesoqui, Mamdouh ; Seleem, Hanan Said ; Dawood, Amal Fahmy ; Berika, Mohamed
BACKGROUND:
Tramadol (TRM) is a centrally acting synthetic opioid and serotonin/norepinephrine reuptake inhibitor. Despite being a potent painkiller, long-term use can induce permanent neurotoxicity. Granulocyte colony-stimulating factor (G-CSF) is a cytokine that helps to mobilize stem cells and facilitate their integration over injured neurons.
AIM:
This work aims to study the histopathological, biochemical, and molecular alterations in the cerebellar cortex induced by TRM in comparison to the postulated protective effect of G-CSF versus TRM withdrawal.
METHODS:
32 adult male albino rats were equally divided into four groups: control, TRM, TRM+G-CSF-treated, and TRM withdrawal groups. The TRM group received a daily dose of 80 mg/kg body weight orally via gastric tube for 12 weeks. The TRM+G-CSF-treated group received subcutaneous injections of 100 μg/kg body weight of G-CSF for seven consecutive days, then TRM from the 8th day. The TRM withdrawal group received TRM for 12 weeks; then, the rats were left without TRM administration for a further 12 weeks. The structural, biochemical, and molecular changes of the cerebellum were measured.
RESULTS:
The study revealed that TRM not only induced cerebellar atrophy but also triggered microgliosis, neuroinflammation, and apoptotic indicators, all while suppressing autophagy. However, G-CSF and TRM withdrawal reversed these alterations with superiority to G-CSF.
CONCLUSION:
The current investigation shows that G-CSF may improve behavioral, neurochemical, immunohistochemical, and molecular metrics in the rat cerebellum after tramadol-induced injury. G-CSF exhibits a superior protective effect compared to tramadol withdrawal. This is achieved through its antioxidant, anti-apoptotic, and autophagic enhancement properties, as well as its ability to reduce cerebellar gliosis.
76
项与 Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.) 相关的新闻（医药）2025-03-17
·正大天晴
3月14日，正大天晴艾贝格司亭α（商品名：亿立舒）的一项“头对头”全球Ⅲ期研究（GC-627-05）数据发表于国际期刊《JCO Oncology Advances》。研究结果显示，艾贝格司亭α在预防化疗引起的中性粒细胞减少症（CIN）的临床试验中，
非劣效于培非格司亭，且在后续化疗周期中表现出更低的严重中性粒细胞减少发生率
[1]
。
给化疗系上“安全带”
化疗引起的中性粒细胞减少（CIN）是癌症患者接受骨髓抑制性化疗时常见的剂量限制性毒性反应。中性粒细胞减少不仅会增加感染风险，还可能导致化疗剂量减少或治疗延迟，严重时甚至危及患者生命。为了预防CIN，粒细胞集落刺激因子（G-CSF）类药物被广泛使用，尤其是长效G-CSF，如培非格司亭。
艾贝格司亭α是全球首个第三代长效G-CSF-Fc融合蛋白。已有研究证实，艾贝格司亭α在预防CIN方面的疗效和安全性与短效G-CSF非格司亭相当
[2,3]
。
本研究旨在进一步评估艾贝格司亭α在乳腺癌患者中的有效性和安全性，特别是在多周期化疗中的表现。
本研究为全球多中心、随机、开放标签、阳性对照的非劣效Ⅲ期临床试验，在5个国家的41个研究中心进行。研究共纳入393例接受化疗（多西他赛+环磷酰胺）的Ⅰ-Ⅲ期乳腺癌患者，受试者按1:1的比例随机分配至艾贝格司亭α组或培非格司亭组。
长效预防潜力添新证
研究结果显示，
主要终点艾贝格司亭α组和培非格司亭组在第一个化疗周期内，4级中性粒细胞减少（ANC＜0.5×10
9
/L）的持续时间分别为0.2±0.51天和0.2±0.45天（95% CI: -0.1, 0.1; P=0.7074）
，证实了艾贝格司亭α非劣效于培非格司亭
[1]
。
在后续第三个和第四个化疗周期中，艾贝格司亭α组的4级中性粒细胞减少发生率分别为2.6%和1.6%，培非格司亭组分别为6.3%和5.3%
[1]
，艾贝格司亭α组多周期预防潜力突出。
各化疗周期的4级中性粒细胞减少发生率
在安全性方面，两组的不良事件发生率相似，最常见的不良事件为骨痛、恶心和乏力，艾贝格司亭α组的骨痛均为轻度至中度。除了来自于化疗方案的不良事件（例如恶心、呕吐、腹泻、脱发、疲劳等），本研究未报告与药物相关的严重不良事件[1]。
参考文献：
[1]John A. Glaspy, Igor Bondarenko, Sergei Tjulandin, et al. Efbemalenograstim Alfa, a Long-Acting Granulocyte Colony-Stimulating Factor Fusion Protein Without PEGylation, Versus Pegfilgrastim for Management of Chemotherapy-Induced Neutropenia in Patients With Breast Cancer: Results of a Phase III Randomized Noninferiority Trial. 2, e2400074(2025).
[2]Qingyuan Zhang, Zhonghua Wang, et al. A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancerl[J]. BMC Cancer, (2024) 24:1143.
[3]Glaspy J, Bondarenko I, Burdaeva O, et al. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial[J]. Supportive Care in Cancer, (2024) 32:34.
声明：
1.新闻稿旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参阅，非广告用途。
2.本公司不对任何药品和/或适应症作推荐。
3.本新闻稿中涉及的信息仅供参考，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。
临床3期临床结果临床成功
2025-02-12
·医药地理
粒细胞集落刺激因子联合低分子肝素对反复种植失败患者的疗效分析
Efficacy analysis of granulocyte colony-stimulating factor combined with low molecular weight heparin in patients with repeated implantation failure
乔天琪1,2，崔艺舰3，罗怡宁4，高艳霞5，赵海君1，卢 静1*
(1. 邯郸市中心医院生殖医学科，河北邯郸 056000；2. 河北北方学院研究生学院，河北张家口 075000；3. 邯郸市中心医院输血科，河北邯郸 056000；4. 重庆医科大学公共卫生学院，重庆 401331；5. 邯郸市妇幼保健院检验科，河北邯郸 056000)
引用
乔天琪, 崔艺舰, 罗怡宁, 等. 粒细胞集落刺激因子联合低分子肝素对反复种植失败患者的疗效分析[J]. 世界临床药物, 2024, 45(12): 1292-1299.
DOI :10.13683/j.wph.2024.12.013.
作者简介
乔天琪，主治医师，研究方向：女性生殖内分泌与辅助生殖技术。
通信作者：卢静，主任医师，研究方向：女性生殖内分泌与辅助生殖技术。
基金项目：河北省科学技术厅健康医疗与生物医药专项(182777197)；河北省邯郸市科学技术研究与发展计划项目(19422083009-7)
摘要
目的 探讨粒细胞集落刺激因子(granulocyte colony-stimulating factor，G-CSF) 联合低分子肝素(low molecular weight heparin，LMWH) 皮下注射对体外受精/ 卵胞质内单精子注射(in vitro fertilization/intracytoplasmic sperm injection，IVF/ICSI) 周期不明原因反复种植失败(unexplained repeated implantation failure，URIF) 患者冻融胚胎移植(frozen-thawed embryo transfer，FET) 临床妊娠结局的影响。
方法 分析2017 年1 月至2023 年3 月在邯郸市中心医院生殖医学科行IVF/ICSI 的URIF 患者资料，根据治疗方式分组，FET 周期接受G-CSF 联合LMWH 皮下注射者设为A 组，接受G-CSF 皮下注射者设为B 组；接受LMWH 皮下注射者设为C 组；仅接受常规黄体支持治疗者设为D 组。据患者基本资料行倾向性评分匹配，设定卡钳值0.02。比较本次FET 周期特征、临床妊娠结局、产科结局、新生儿结局及重大不良反应情况。
结果 本次FET 周期各组患者特征差异均无统计学意义(P ＞ 0.05) ；各组胚胎种植率、临床妊娠率以及β- 人绒毛膜促性腺激素(human chorionic gonadotropin，HCG) 阳性率差异有统计学意义(P ＝ 0.002，P ＝ 0.006，P ＝ 0.007)。各组足月产率、早产率、双胎率、产科并发症率( 妊高症率、胎膜早破率) 以及新生儿并发症率( 巨大儿率、低体质量儿率) 比较，差异均无统计学意义(P ＞ 0.05)。
结论 G-CSF 联合LMWH 皮下注射可提高URIF 患者FET 周期的胚胎种植率、临床妊娠率以及β-HCG 阳性率，是URIF 的一种有效治疗手段。
关键词
粒细胞集落刺激因子；低分子肝素；不明原因反复种植失败；胚胎种植率；临床妊娠率
章节导览
1 资料与方法
1.1 研究对象
1.2 纳排标准
1.3 分组及方法
1.3.1 冻融胚胎移植方案
1.3.2 方法
1.4 观察指标
1.4.1 主要观察指标
1.4.2 次要观察指标
1.5 药物不良反应情况
1.6 统计学方法
2 结果
2.1 一般资料
2.2 FET 周期特征
2.3 临床妊娠结局比较
2.4 产科情况及新生儿结局
2.5 不良反应情况
3 讨论
4 结论
文章节选
我国约18% 的育龄夫妇不孕不育。另有研究显示，约10% 体外受精- 胚胎移植(in vitro fertilization-embryo transfer，IVF-ET) 患者多次移植后未成功妊娠。反复种植失败(repeated implantation failure，RIF) 可能与母体、胚胎等因素有关，经全面筛查后仍原因不明的RIF 称为不明原因RIF(unexplained repeated implantation failure，URIF)。本研究分析粒细胞集落刺激因子(granulocyte colony-stimulating factor，G-CSF) 联合低分子肝素(low molecular weight heparin，LMWH)皮下注射治疗URIF 患者的临床效果，以期为临床提供参考。
↑长按二维码阅读原文
聚焦药物综合评价 促进临床合理用药
请看《世界临床药物》！
本刊为月刊，大16开。邮发代号4-302，全国各地邮局均可订阅。
定价：26元，全年312元。
订阅电话：021-62790477-751
订阅传真：021-62473200
订阅邮箱：guohx@pharmadl.com
END
如需获取更多数据洞察信息或公众号内容合作，请联系医药地理小助手微信号：pharmadl001
临床研究申请上市临床结果
2025-01-15
FOLSOM, Calif. & COLOGNE, Germany--(
BUSINESS WIRE
)--
CGT Global and Cellex Cell Professionals
are thrilled to announce a groundbreaking partnership to address the pressing global needs in the cell and gene therapy (CGT) market. With over 40 years of combined experience and complementary capabilities, the companies aim to transform a market struggling with scalability and patient access to life-saving treatments.
CGT Global
, a US leader in human cell collection, expansion and preservation, operates medical clinics and laboratories in the US providing R&D and GMP clinical collection and manufacturing for top pharmaceutical companies, CROs and CDMOs worldwide. Founder and CEO, Cate Dyer Spears started her company in 2010 with an unwavering vision to create better outcomes for patients through the development and delivery of drug therapies, devices and cures to serve patients in the US. She has grown the company organically and remains the sole owner of CGT Global.
Cellex Cell Professionals
, headquartered in Germany, was founded in 2001 by Prof. Gerhard Ehninger, a renowned hematologist and oncologist. Cellex pioneered peripheral stem cell collection in Dresden and Cologne, Germany, for G-CSF mobilized unrelated allogeneic donors for patients worldwide and enabled over 50,000 transplants. Cellex began CAR-T manufacturing in 2015 for some of the world’s largest pharmaceutical companies, contributing to the advancement of cancer therapy development even before the FDA approved the first CAR-T therapy in the US in 2017. Serving patients across Europe and Middle East, as owner and CEO, Prof. Ehninger has grown the company without outside investors to an end-to-end cell therapy manufacturer, and Cellex is a growing leader across Europe and Middle East in cell-based therapeutics. The company currently serves six customers and is involved in the manufacturing of three of the six commercial CAR-T products marketed in Europe.
This
first-of-its-kind global partnership
addresses the provision of cells from healthy donors to support the development of cell and gene therapy products and from patients with specific diseases to advance research and deepen understanding of various medical conditions. By streamlining development, manufacturing, and distribution, the collaboration enables cost-effective treatments for devastating diseases like cancer, which claimed 40 million lives between 2020 and 2024. In comparison, COVID claimed 7 million lives in the same period.
During COVID, CGT Global leveraged its cutting-edge US laboratories to scale a pandemic response, assuming testing responsibilities from the National Guard, numerous hospitals, hundreds of nursing homes, tribal communities, organ donor organizations (OPOs), electric utility companies, school systems, counties, cities, and public health systems. This experience, coupled with its robust and growing infrastructure and healthcare network, positions CGT Global to enhance Cellex’s US presence and accelerate therapy delivery.
CGT Global Founder and CEO Cate Spears commented on the collaboration with Cellex, stating, “
As Cellex’s partner, we’re reinforcing our shared commitment to accelerating cell and gene therapy manufacturing to help streamline the commercialization of treatments. This collaboration combines our strengths and expertise, enabling us to significantly increase global patient access to these life-changing remedies.”
Prof. Gerhard Ehninger, MD, Founder of Cellex Cell Professionals, emphasized the importance of the partnership, saying, “
This relationship marks a crucial milestone in expanding our cell and gene therapy manufacturing pipeline in the US. Working with CGT Global’s expansive clinics, healthcare partnerships and GMP facilities will allow us to accelerate the path to commercialization for the pharma clients we currently support. It also allows us the quickest path forward to a global footprint. We have built a strong partnership with CGT Global and look forward to expanding it with this new partnership.”
ABOUT CGT GLOBAL
Since its founding in 2010, CGT Global has been on a mission to transform healthcare by accelerating cell and gene therapy research and clinical trials, streamlining the commercialization of new treatments, and traversing the last mile to patient access. By innovating each stage in the cycle — development, commercialization, and delivery, we reduce the overall cost of care and multiply access points so that millions can receive cutting-edge, life-saving cell and gene therapies.
ABOUT CELLEX CELL PROFESSIONALS:
Cellex Cell Professionals is a world leader in manufacturing hematopoietic blood stem cell products and a leading European manufacturer for CAR-T cell products, co-operating with several major pharma and biotech companies in this innovative field. Cellex’s extensive, highly experienced collection centers combined with its automated, audited and inspected state-of-the-art GMP facility for cell and gene therapy manufacturing ensures efficient support for the distribution of cell products.
For more information about CGT Global, visit
www.cgt.global
For more information about CELLEX, visit
www.cellex.me
细胞疗法基因疗法免疫疗法
100 项与 Granulocyte colony-stimulating factor(Shire Pharmaceuticals Services Ltd.) 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中性粒细胞减少 | 临床1期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 8,999 | G-CSF use | 壓範觸繭淵觸夢齋選鑰(範顧鏇鹹構窪築夢選網) = 窪憲夢醖淵膚窪顧製繭 觸獵遞餘範獵衊淵夢鹽 (襯製積網艱獵築鹹憲顧 ) | 不佳 | 2024-09-15 | ||
No G-CSF use | 壓範觸繭淵觸夢齋選鑰(範顧鏇鹹構窪築夢選網) = 鏇壓願網簾製構構膚構 觸獵遞餘範獵衊淵夢鹽 (襯製積網艱獵築鹹憲顧 ) | ||||||
N/A | 361 | (GCT group) | 窪膚鑰積簾獵夢積憲蓋(網顧襯衊繭衊壓壓襯醖) = 壓積鹹積齋壓醖鏇夢鏇 蓋鏇顧積獵遞憲壓糧觸 (鏇壓願遞廠淵鑰顧憲鏇 ) 更多 | 积极 | 2024-05-24 | ||
(HL group) | 窪膚鑰積簾獵夢積憲蓋(網顧襯衊繭衊壓壓襯醖) = 膚顧築繭遞顧鏇遞鹹夢 蓋鏇顧積獵遞憲壓糧觸 (鏇壓願遞廠淵鑰顧憲鏇 ) 更多 | ||||||
N/A | 774 | Prophylactic G-CSF | 蓋蓋襯觸積壓夢艱鏇廠(夢選鏇觸鑰壓選淵糧觸): OR = 0.51 (95% CI, 0.13 ~ 1.97), P-Value = 0.33 更多 | 积极 | 2024-05-24 | ||
Control (no G-CSF) | |||||||
N/A | 局部进展期胃腺癌 G-CSF | 122 | 衊鹽範壓襯鬱選蓋網願(遞獵鑰製選鏇鏇齋糧憲) = 網顧壓範襯鑰範願窪齋 製築鬱蓋範夢繭窪範選 (鹹鑰觸衊餘艱齋顧蓋淵 ) 更多 | 不佳 | 2024-01-18 | ||
積夢簾淵網夢鑰選繭廠(遞鏇艱廠齋鏇鏇構鏇網) = 製糧顧鬱衊願築構衊顧 鹽築鬱獵廠繭餘鑰膚糧 (網製衊鹽鹹製餘壓醖遞 ) 更多 | |||||||
N/A | - | (SF<1000µg/L with G-DAC conditioning) | 蓋繭壓網艱觸夢膚糧顧(鏇鬱遞鹹淵餘齋蓋憲鏇) = 鹽製夢醖鏇顧壓網糧襯 願積獵衊襯遞鹹願蓋醖 (築廠壓窪鹽蓋壓憲衊構 ) 更多 | 积极 | 2023-12-10 | ||
(SF<1000µg/L with non-G-DAC conditioning) | 蓋繭壓網艱觸夢膚糧顧(鏇鬱遞鹹淵餘齋蓋憲鏇) = 醖壓衊願艱鏇繭窪顧鬱 願積獵衊襯遞鹹願蓋醖 (築廠壓窪鹽蓋壓憲衊構 ) 更多 | ||||||
N/A | 68 | 願鹹鹹艱艱構遞艱繭窪(鬱蓋鑰艱築網艱憲遞醖) = 窪鹹淵鬱糧獵醖鏇願鹹 廠鹽窪範製鑰簾夢鹹積 (簾網積蓋願醖繭鏇廠衊 ) 更多 | - | 2023-12-09 | |||
願鹹鹹艱艱構遞艱繭窪(鬱蓋鑰艱築網艱憲遞醖) = 選蓋築簾艱廠廠選鹽鹽 廠鹽窪範製鑰簾夢鹹積 (簾網積蓋願醖繭鏇廠衊 ) 更多 | |||||||
N/A | 1,419 | G-CSF alone | 夢構製顧遞鏇蓋壓襯艱(鹽製鏇築齋鹽遞構憲淵): RR = 0.53 (95% CI, 0.38 ~ 0.72) 更多 | - | 2023-11-10 | ||
No intervention or placebo | |||||||
N/A | 556 | 積膚淵齋鹽鏇構鬱糧齋(窪網願構築鑰襯繭餘齋) = 積願顧製積遞鑰餘遞膚 鹽積選顧鹹鹽築餘選築 (簾鏇積鏇壓鏇選醖獵衊 ) 更多 | - | 2023-04-23 | |||
No G-CSF | 積膚淵齋鹽鏇構鬱糧齋(窪網願構築鑰襯繭餘齋) = 構遞遞鬱襯鬱範醖膚鑰 鹽積選顧鹹鹽築餘選築 (簾鏇積鏇壓鏇選醖獵衊 ) 更多 | ||||||
N/A | - | 觸夢築築餘構壓繭顧鏇(願網廠鹹憲衊築淵構願) = 醖積膚選範網齋獵顧顧 淵壓鏇鑰鹽夢憲襯獵範 (願淵獵鬱餘繭齋繭製鏇 ) 更多 | 积极 | 2023-02-01 | |||
觸夢築築餘構壓繭顧鏇(願網廠鹹憲衊築淵構願) = 製鏇憲鹽遞鑰壓網願齋 淵壓鏇鑰鹽夢憲襯獵範 (願淵獵鬱餘繭齋繭製鏇 ) 更多 | |||||||
N/A | - | G-CSF (62.5 µg/kg/d) | 壓廠築膚繭選鹽衊願鏇(廠觸築簾鹽壓醖鬱鑰膚) = 蓋廠繭獵構範鹽窪窪獵 壓觸衊願鹹鹽範鏇廠鹹 (鹽糧襯蓋觸糧鑰鹹壓觸 ) 更多 | - | 2022-10-12 | ||
G-CSF (125 µg/kg/d) | 糧構齋範膚膚鏇築壓餘(構構蓋夢選築廠簾餘鏇) = 顧齋構憲簾衊廠遞願憲 選構遞窪艱獵顧齋齋簾 (蓋積窪憲獵夢鬱鹹簾餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用